BioHealth Investor » OCLS http://biohealthinvestor.com Biotech and Medical Business Information Sat, 31 Jul 2010 00:09:03 +0000 en hourly 1 http://wordpress.org/?v=3.0.1 Oculus Innovative Sciences (OCLS) Gets Reimbursement Approval http://biohealthinvestor.com/2009/09/oculus-innovative-sciences-ocls-gets-reimbursement-approval.html http://biohealthinvestor.com/2009/09/oculus-innovative-sciences-ocls-gets-reimbursement-approval.html#comments Thu, 10 Sep 2009 13:41:58 +0000 247admin http://www.biohealthinvestor.com/?p=2180 Oculus Innovative Sciences (OCLS) shares are up over 8% to $2.78, near their 52-week high. The stock’s period low is $.20.

The company announced that Noridian Administrative Services LLC, which is the pricing, data analysis and coding contractor for the Medicare program with respect to durable medical equipment, prosthetics, orthotics, and medical supplies, has assigned a Medicare HCPCS code for Oculus’ recently introduced Microcyn Skin & Wound HydroGel.

The HCPCS code #A6248 provides for 80% reimbursement of $17.05 per ounce. Reimbursement is provided for up to three ounces per month per patient wound.

Douglas A. McIntyre

]]> http://biohealthinvestor.com/2009/09/oculus-innovative-sciences-ocls-gets-reimbursement-approval.html/feed 0